BIOMARKER RESULTS FROM PENELOPE, A RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY plus /- PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC) WITH LOW TUMOUR HER3 MRNA EXPRESSION

被引：0
|
作者：
Colombo, N. [1 ,2 ]
Gonzalez-Martin, A. [3 ,4 ]
Oestergaard, M. Z. [5 ]
Rau, J. [6 ]
Canzler, U. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Martinez, J. [11 ,12 ]
Kiermaier, A. [5 ]
Mitchell, L. [13 ]
Kurzeder, C. [14 ,15 ]
机构：
[1] Univ Milano Bicocca, Div Med Gynecol Oncol, MaNGO, Milan, Italy
[2] Univ Milano Bicocca, European Inst Oncol, Milan, Italy
[3] GEICO, Dept Med Oncol, Madrid, Spain
[4] MD Anderson Canc Ctr Spain, Madrid, Spain
[5] F Hoffmann La Roche, Oncol Biomarker Dev, Basel, Switzerland
[6] Univ Marburg, Coordinating Ctr Clin Trials, Marburg, Germany
[7] AGO, Dept Gynecol & Obstet, Dresden, Germany
[8] Univ Hosp Carl Gustav Carus, Dresden, Germany
[9] GINECO, Dept Med Oncol, Montpellier, France
[10] Ctr Lutte Canc Val dAurelle, Montpellier, France
[11] GEICO, Dept Med Oncol, El Palmar, Spain
[12] Hosp Virgen Arrixaca, El Palmar, Spain
[13] F Hoffmann La Roche, Global Med Affairs Biometr, Basel, Switzerland
[14] AGO, Dept Med Oncol, Essen, Germany
[15] Kliniken Essen Mitte, Essen, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1093
引用
收藏
页码：415 / 417
页数：3
相关论文
共 43 条
  • [31] BIOMARKER (BM) RESULTS FROM GOG-0218, A PHASE 3 TRIAL OF FRONT-LINE BEVACIZUMAB (BV) plus CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC)
    Birrer, M. J.
    Lankes, H.
    Burger, R. A.
    Mannel, R.
    Homesley, H.
    Henschel, V.
    Sovak, M.
    Scherer, S. J.
    de Haas, S.
    Pallaud, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 81 - 82
  • [32] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
    Bello, Diana
    Van Gorp, Toon
    Konecny, Gottfried E.
    Estevez-Garcia, Purificacion
    Moroney, John William
    Banerjee, Susana N.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Parma, Gabriella
    Sonnenburg, DanielW
    Roszak, Andrzej
    Lalisang, Roy Iqbal
    Shapira-Frommer, Ronnie
    Klat, Jaroslav
    Wang, Yuemei
    Method, Michael W.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial: Mirvetuximab Soravtansine (MIRV) Prolongs Overall Survival vs Investigator's Choice Chemotherapy (IC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha (FRa) Expression
    Hilpert, Felix
    Harter, Philipp
    Lorusso, Domenica
    Konecny, Gottfried. E.
    Banerjee, Susana
    Colombo, Nicoletta
    Wang, Yuemei
    Stec, James
    Method, Michael
    Van Gorp, Toon
    Moore, Kathleen
    de Gregorio, Nikolaus
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 91 - 91
  • [34] Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator's choice chemotherapy: analysis from the phase 3 MIRASOL trial
    Garcia, Yolanda Garcia
    Gorp, Toon Van
    Konecny, Gottfried E.
    Leary, Alexandra
    Santin, Alessandro D.
    Crusz, Shanthini Mary
    Mantia-Smaldone, Gina
    Lorusso, Domenica
    Colombo, Nicoletta
    Thomes-Pepin, Jessica
    Roszak, Andrzej
    Ottevanger, Petronella B.
    Beiner, Mario
    Cibula, David
    Leath, Charles
    Li, Lingling
    Method, Michael
    Moore, Kathleen N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A34 - A35
  • [35] Model prediction of mean PFS and OS Time from a phase II trial comparing vintafolide (V) plus pegylated liposomal doxorubicin (PLD), versus PLD alone, in platinum-resistant ovarian cancer (PROC) patients with 100% folate receptor (FR) positive target lesions
    Herzog, T.
    Anderson, K.
    Wang, J.
    Xu, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S732 - S733
  • [36] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
    Im, S-A.
    Tan, A. R.
    Mattar, A.
    Colomer, R.
    Stroyakovskii, D.
    Nowecki, Z.
    De Laurentiis, M.
    Pierga, J-Y.
    Jung, K. H.
    Schem, C.
    Aguila, C.
    Crnjevic, T. Badovinac
    Heeson, S.
    Shivhare, M.
    Alexandrou, A.
    Restuccia, E.
    Jackisch, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S40 - S41
  • [37] Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
    Kurtz, J. E.
    Pujade-Lauraine, E.
    Oaknin, A.
    Belin, L.
    Grimm, C.
    Kocian, R.
    Denys, H.
    Rosengarten, O. S.
    Follana, P.
    Sehouli, J.
    Martinez-Garcia, J.
    Alexandre, J.
    Hardy-Bessard, A-C.
    Frenel, J-S.
    Sabatier, R.
    Gladieff, L.
    Rouge, T. De La Motte
    Lamichhane, N. Bonichon
    Kalbacher, E.
    Heitz, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S546 - S546
  • [38] PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intraperitoneal Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Bakrin, Naoual
    Tempfer, Clemens
    Scambia, Giovanni
    De Simone, Michele
    Gabriel, Boris
    Grischke, Eva-Maria
    Rau, Beate
    Oncologic, French
    PLEURA AND PERITONEUM, 2018, 3 (03)
  • [39] Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
    Reck, Martin
    Schenker, Michael
    Lee, Ki Hyeong
    Provencio, Mariano
    Nishio, Makoto
    Lesniewski-Kmak, Krzysztof
    Sangha, Randeep
    Ahmed, Samreen
    Raimbourg, Judith
    Feeney, Kynan
    Corre, Romain
    Franke, Fabio Andre
    Richardet, Eduardo
    Penrod, John R.
    Yuan, Yong
    Nathan, Faith E.
    Bhagavatheeswaran, Prabhu
    DeRosa, Michael
    Taylor, Fiona
    Lawrance, Rachael
    Brahmer, Julie
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 137 - 147
  • [40] Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1-and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer
    Penson, Richard
    Valencia, Ricardo Villalobos
    Colombo, Nicoletta
    Leath, Charles
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo
    Ryu, Sang-Young
    Milenkova, Tsveta
    Lowe, Elizabeth
    Lukashchuk, Natalia
    McNamara, John
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S20
12345